Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy

· Peking University People's Hospital

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy, covering 2026-03-30 to 2026-03-30. Get the full timeline:

Most recent: Clinical Trial Update: Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL [Phase 1, Phase 2]

See pricing